Cargando…
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma
Reliable biomarkers are required to predict the response to sorafenib. We investigated genomic variations associated with responsiveness to sorafenib for patients with unresectable hepatocellular carcinoma (HCC). Blood samples from 2 extreme, 2 strong and 3 poor responders to sorafenib were subjecte...
Autores principales: | Lee, Yeon-Su, Kim, Bo Hyun, Kim, Byung Chul, Shin, Aesun, Kim, Jin Sook, Hong, Seung-Hyun, Hwang, Jung-Ah, Lee, Jung Ahn, Nam, Seungyoon, Lee, Sung Hoon, Bhak, Jong, Park, Joong-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599281/ https://www.ncbi.nlm.nih.gov/pubmed/25965825 |
Ejemplares similares
-
Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?
por: Lee, Jayoung, et al.
Publicado: (2017) -
Genomic profile analysis of diffuse-type gastric cancers
por: Lee, Yeon-Su, et al.
Publicado: (2014) -
Genomic landscape of extraordinary responses in metastatic breast cancer
por: Lim, Sun Min, et al.
Publicado: (2021) -
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019) -
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
por: Oh, Chung Ryul, et al.
Publicado: (2019)